The definition of tumor deposits (TDs) in colonic adenocarcinoma has been modified in different editions of the AJCC/TNM staging system. Studies have shown that the presence of TD is associated with advanced tumor growth and poor prognosis. Most of these data were obtained in patients with simultaneous lymph node (LN) metastases. Reports focusing on the impact of TD in patients without LN metastasis are limited. We retrospectively restaged all right-sided colonic adenocarcinomas over a 10-year period using criteria from the fifth, sixth, and seventh AJCC edition. We compared the number of tumor nodule interpreted as LN and TD in each edition and evaluated the stage migration caused by TD definition change. We then assessed clinical significance of TD in the AJCC seventh edition by comparing 5-year overall survival of N1c patients versus other N category (N0, N1, N2) patients with similar T and M status. We showed that the average number of tumor nodules interpreted as LNs per case and the number of cases with positive LNs were significantly decreased with the seventh edition compared with fifth/sixth; however, numbers of cases with TDs and <12 LNs were significantly increased with the seventh edition compared with fifth/sixth. These changes, however, resulted in minimal effects on the final stage grouping. Our survival analysis showed that N1c patients had significantly worse survival compared with N0 patients. Although not statistically significant, the hazard ratios indicated that the N1c group might have worse survival than the N1 group and better survival than the N2 group. Therefore, we conclude that TDs predict patient outcome at least similarly to positive LNs.
T umor deposits (TDs) in the pericolorectal adipose tissue of patients with colorectal adenocarcinoma have been recognized since early in the 20th century. 1 The major origins of TD include discontinuous tumor spread, venous invasion with extravascular spread, or a totally replaced lymph node (LN). Over the years, the definition and clinical impact of TDs have been discussed among pathologists, surgeons, and clinical oncologists. The definition of TD versus LN has been revised from the fifth, the sixth, to the most recent seventh edition of the American Joint Committee on Cancer (AJCC)/Tumor Node Metastasis (TNM) staging system ( Fig. 1) . TDs were first introduced in the fifth edition of the AJCC/ TNM staging system in 1997, [2] [3] in which tumor nodules >3 mm in diameter without histologic evidence of a residual LN were classified as regional LN metastasis; however, tumor nodules r3 mm were classified in the T category as a discontinuous extension. In the next edition (sixth, 2002), 4-5 the 3 mm size rule was withdrawn, and the new classification was based on the contour. If the tumor nodules had the form and smooth contour of an LN, they were classified as regional LN metastasis; if the nodules had an irregular contour, they were classified as discontinuous extension. In the most recent seventh edition (2010), [6] [7] TDs were defined by identifying features of residual LN architecture instead of using a specific size and contour rule. Discrete foci of tumor in the pericolorectal fat showing no evidence of residual LN tissue are considered to be peritumoral TDs, and their number should be recorded in the pathology report. In addition, TDs were moved from their prior involvement of T category to the formation of a new nodal subclassification of N1c, if there is no concurrent positive LN.
The goal of cancer staging is to provide evidencebased guidelines for clinical decision-making in treatment plans, clinical trial candidacy, and estimating prognosis. Studies have shown that the presence of TD is associated with advanced tumor growth and poor prognosis. [8] [9] [10] Most of these data were obtained in patients with simultaneous LN metastases. Reports focusing on the impact of TD in patients without LN metastasis are limited but vital to determining the importance of TD.
In this study, we retrospectively collected and restaged all right-sided colonic adenocarcinomas over a 10-year period from our institution using criteria from each AJCC edition. We compared the number of LNs and TDs in each edition, and evaluated the stage migration caused by TD definition change. We then assessed the clinical significance of TD by comparing the 5-year overall survival of N1c patients versus other N category patients with similar T and M status. The new category of N1c in the seventh edition was created to allow data collection and outcome analysis to be performed to better understand the clinical significance of TD. We aim to provide more evidence and rationale for the future AJCC/TNM staging system.
MATERIALS AND METHODS

Patient Selection
All right-sided primary colonic adenocarcinomas (438 cases) with available slides over a 10-year period (2001 to 2010) at the Ohio State University Wexner Medical Center were retrieved and reviewed by pathologists with an interest in gastrointestinal pathology.
For 5-year survival comparisons between N1c tumors with N0, N1 (N1a and N1b), and N2 tumors, we first excluded all Tis, T1, and T2 patients (n = 97), as only 2 cases were T2N1c, and none of the T1 cases were N1c. In addition, 57 cases with positive M status were also excluded, as well as 1 case with a survival time of zero. Therefore, our comparison groups similarly included T3 and T4 tumors without distant metastasis. From the original cohort of 438 adenocarcinomas, there were 283 T3 or T4 and M0 cases that were used in survival calculations.
Staging Using AJCC Fifth, Sixth, and Seventh Editions
All cases were restaged using AJCC fifth, sixth, and seventh edition criteria with particular attention paid to the precise definitions of TD, metastatic LN, and the depth of invasion. Stage migration due to TD definition change between sixth and seventh editions was assessed by comparing TNM stage and stage grouping status in each case.
Statistical Methods for Staging and Survival
Both TD and LN were compared between the 3 different editions. The average LNs per case was estimated with 95% confidence intervals (CI) for each edition separately using repeated measures analysis of variance. From the model, differences in the average number of LNs between the fifth and sixth editions with the average number of LNs in the seventh edition were assessed. The McNemar test was used to compare the proportions of patients with TD, <12 LNs, and at least 1 positive LN in the fifth and sixth editions with those in the seventh edition.
For 5-year survival analysis, age and sex were compared between the 4 N groups (N1c, N0, N1, and N2) within the survival cohort using analysis of variance and a w 2 test, respectively. Kaplan-Meier estimates of the survival function were produced to assess crude differences in 5-year survival, and the log-rank test was performed to test for differences in survival functions. Estimated hazard ratios (HR) and 95% CI for N1c versus N0, N1, and N2 were calculated from both univariable (unadjusted) and age-adjusted Cox proportional hazards models. Note that sex and year of resection were initially considered as adjustment factors in addition to age; however, because of lack of evidence of being either significant predictors or confounders/effect modifiers of the relationship between N group and survival, they were not included in the final adjusted model. For both the univariable and age-adjusted models, the proportional hazards assumption for each variable in the model was assessed both graphically FIGURE 1 . Two examples of TD versus LN in fifth, sixth, and seventh editions of the AJCC/TNM staging system. A and B, Both tumor nodules would be classified as LN in the fifth edition because their sizes are >3 mm; they would be classified as LN in the sixth edition because they have a round shape; and they would be classified as TD in the seventh edition because there is no definite residual LN (hematoxylin-eosin stain). and by including the interaction with time (natural log scale); no serious deviations were observed. All analyses were performed using SAS/STAT software version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Staging Using AJCC Fifth, Sixth, and Seventh Editions
A comparison summary of both LN and TD for our 438 cases by edition is shown in Table 1 . The estimated average number of tumor nodules interpreted as LNs per case on the basis of the seventh edition was 21.2 (95% CI: 20, 22.3), which was significantly lower than the estimated LNs per case according to both the fifth (estimated LNs per case = 22.2; 95% CI: 21, 23.4) and sixth (estimated LNs per case = 21.9; 95% CI: 20.8, 23) editions (P < 0.001 for both comparisons). Similarly, the number of cases with positive LNs was significantly lower in the seventh edition compared with both the fifth and sixth editions (161 in the seventh edition vs. 180 for both the fifth and sixth editions; P < 0.001 for both comparisons). Conversely, the number of cases with TDs and the number of cases with <12 LNs were both significantly increased in the seventh compared with fifth/sixth editions (for TD: 123 in the seventh edition vs. 53 and 65 in the fifth and sixth editions, respectively; for <12 LNs: 71 in the seventh edition vs. 50 and 55 in the fifth and sixth editions, respectively; P < 0.001 for all comparisons).
Nineteen (4%) of 438 cases showed a stage grouping migration between sixth and seventh editions due to TD definition change. The stage grouping migration in all 19 cases was caused primarily by an N category change. Of these 19 cases, 13 downmigrated from IIIC in the sixth to IIIA/B in the seventh due to a change from N2 in the sixth to N1 (N1a, N1b, and N1c) in the seventh; and 6 upmigrated from IIA/B in the sixth to IIIB/C in the seventh due to a change from N0 in the sixth to N1c in the seventh. No stage grouping migration in these 19 cases was caused by a T category change. Nineteen (4%) of 438 cases had an N category change due to TD definition change but did not cause final stage grouping migration because of concurrent M1 status.
Thirty-two (7%) of 438 cases had stage grouping migration due to expanded subclassification in AJCC seventh edition.
Survival Analysis
Of the 438 patients in our study, 283 were T3 or T4 with M0 status. These patients were separated into 4 groups on the basis of the N status ( Table 2) : 17 were N1c, 162 were N0, 69 were N1 (N1a and N1b), and 35 were N2. There were no significant differences in sex (P = 0.326) between different N groups; for age, it appears as though N1 patients were significantly younger compared with N0 patients (mean age 62.5 vs. 68.5 y; P = 0.020). No other age differences between groups were noted.
Overall 5-year survival of patients with N1c tumor was compared with that of N0, N1, and N2. One hundred thirty-seven of 283 (48%) patients died within 5 years of resection. Kaplan-Meier estimates of the survival function for each N group are shown in Figure 2 , and the median survival times with 95% CI and log-rank test results for each N group are given in Table 3 . Note that 67% of the N0 patients were censored at 5 years; consequently, the median survival time could not be calculated for this group. On the basis of the survival curves, N1c patients appeared to have worse survival compared with N0 patients (log rank P < 0.001). Although the median survival time of N1c (23.5 mo; 95% CI: 11.5, 41.0) was shorter than that of N1 (31.4 mo; 95% CI: 19.5, 48.1; P = 0.208) and longer than that of N2 (16.7 mo; 95% CI: 7.9, 24.8; P = 0.179), the CIs were wide, reflecting the relatively small sample sizes, and differences were not statistically significant.
The univariable (unadjusted) HRs for N0, N1, and N2 versus N1c with 95% CI from a Cox proportional hazards model are shown in Table 4 . Compared with N1c, N0 was protective in terms of survival: the HR was 0.32 (< 1), meaning that the death rate throughout the follow-up period for patients with N0 was roughly one third the death rate of patients with N1c (95% CI: 0.18, 0.61; P < 0.001). Similarly, the HR for N1 versus N1c was also <1, although not statistically significant (estimated HR = 0.66; 95% CI: 0.36, 1.28; P = 0.192). The HR for N2 versus N1c was >1, implying that the rate of death was greater for N2 compared with N1 throughout the follow-up period; again this difference was not statistically significant (P = 0.231). Results from the ageadjusted model were similar to the univariable model. The log-rank test as well as the univariable and ageadjusted Cox models all indicated that there were significant survival differences between N1 (N1a, N1b) and N2, which validated the existing TNM staging rationale.
The number of TDs in our 17 N1c cases ranged from 1 to >20. To evaluate the potential impact of TD number on N1c patient survival, we divided these patients into 2 groups on the basis of the number of TDs; the cutoff point of 4 TDs was chosen on the basis of the current N-stage system of N1 (positive LN < 4, N1a and N1b) and N2 (positive LNZ4). As a sensitivity analysis, we explored different cutoff points according to our data ( Table 5 ). Note that there were no cases with 6 or 7 TDs, and therefore we could not consider 6 or 7 TDs as potential cutoff points. In addition, there are only 4 patients with Z8 TDs, making higher cutoff points not feasible. Cutoff points of 4 TDs and 5 TDs both resulted in significant differences in survival, on the basis of the logrank test. Note, however, that the CIs for median survival times are very wide, reflecting the fact that we only had information on 17 patients. Although our data are limited, these results do appear to provide some support of the cutoff point chosen on the basis of N-stage system of N1 (positive LN < 4, N1a and N1b) and N2 (positive LNZ4). Kaplan-Meier estimates of the survival function using a cutoff point of 4 TDs are shown in Figure 3 , and median survival times with 95% CI are presented in Table 5 . Note that the median survival time for N1c patients with <4 TDs was 32.5 months (95% CI: 11.5, 55.6) compared with only 16.5 months for N1c patients with Z4 TDs (95% CI: 1.5, 24.1). Estimates from the univariable Cox model using a cutoff point of 4 TDs are shown in Table 6 . Although not statistically significant, it appeared as though patients with N1c: <4 TDs might have superior survival compared with N1c: Z4 TDs (estimated HR = 0.37; 95% CI: 0.12, 1.25; P = 0.087).
DISCUSSION
In this study, we included all right-sided primary colonic adenocarcinomas with available slides over a 10-year period in our institution. We limited our analysis to right side colon cancers to minimize any potential effects on outcome due to tumor site. We avoided any rectal or even low sigmoid cancer that may have had pretreatment. Rectal cancer patients usually receive neoadjuvant therapy preoperatively, and the prognostic significance of TD in these patients may be different from that in the right-sided colon cancer patients without neoadjuvant therapy. 8, 11 A recent study has shown that TD in rectal adenocarcinoma after neoadjuvant chemoradiation has been associated with poor prognosis. 12 We found that the development of the new N1c category and changes to the definition of TD in the AJCC seventh edition affected the number of tumor nodules interpreted as LNs per case, and the number cases with positive LNs, TDs, and <12 LNs after extensive LN search. In our study, the incidence of TD was 29% (123/ 438), and the incidence of LN metastasis was 37% (161/ 438) using seventh edition. These data are similar or within the range of previous reports. 9, 13 Oncologists and surgeons should expect the number of cases with <12 LNs to significantly increase, as some of those previously counted as LNs are now considered TDs. This will likely have a minimal clinical impact, as all of these patients will be considered at least N1 and staged as III and likely receive additional treatment.
The TD definition change resulted in only minimal effects on the final stage grouping between sixth and seventh editions. Only 4% (19/438) showed a stage grouping migration due to TD definition change between sixth and seventh editions. The stage grouping migration was present in both directions and was caused primarily by N category change. None of the stage grouping migration was caused by T category change. Although the stage downmigration from IIIC to IIIA/B probably would not make much difference in clinical management, the stage upmigration from IIA/B to IIIB/C could result in additional treatment. Nagtegaal et al 9 reported that every change in edition of TNM led to a stage migration of between 33% and 64% in patients with TD. Several study design differences can explain the lower percentage of stage grouping migration that we found. Firstly, we included all the colon cancer patients for calculation; Nagtegaal and colleagues only included the patients with TD. When we limited our cohort to consider only the patients with TD, 15% (19 of 123) of cases with TD showed final stage migration due to TD definition changes. In addition, another 15% (19 of 123) of cases with TD had N category change due to TD definition change but did not cause stage grouping migration because of concurrent M1 status. Secondly, our findings were calculated from the migration change only due to TD definition change, and the changes due to expanded subclassification were not included. There were 7% (32 of 438) of our total cases with stage grouping migration due to expanded subclassification in the AJCC seventh edition. Lastly, the patient population in the previous study was from Europe, whereas our patient cohort was from the United States. Studies have shown that the presence of TD is associated with advanced tumor growth including higher T stage, LN, and distant metastases, positive circumferential resection margin, poor differentiation, and extramural vascular invasion as well as poor prognosis. [8] [9] [10] [13] [14] [15] [16] [17] Most of these data were obtained in patients with simultaneous LN metastases. Whether this still holds true for patients without LN metastases has not been well studied. Only limited reports from China 16 and the Netherlands 18 have discussed the prognostic value of TD in patients without LN metastasis and suggested that the seventh ed-ition of TNM staging satisfactorily predicts patients' outcome for those without LN metastasis. To better address the sole impact of TD on survival in our population, our survival analysis focused on N1c patients versus N0 or N1 (N1a and N1b) or N2 patients with similar T and M status. Our study showed that N1c patients had significantly worse outcome compared with N0 patients. Although no statistically significant differences were found between the groups of N1c and N1 or N1c and N2, the HR indicated that the N1c group might have worse survival compared with the N1 group and better survival than the N2 group. Our data suggest that TD with no LN metastasis may behave similarly to positive LN, which supports the creation of the new category of N1c in the seventh edition, as it would upgrade patients into stage III and likely result in additional chemotherapy. As interobserver variability exists, 19 some recent studies have proposed to classify TD as LN to decrease the subjectivity in assessments of TD. 17, 20 We further investigated whether the number of TDs affects patient survival. Our analysis showed that the cutoff points of 4 TDs and 5 TDs resulted in significant differences in survival on the basis of the log-rank test. Although it was difficult to estimate survival in the TD The Impact of Tumor Deposits on Colon Cancer Staging subgroups as shown by the wide CIs for median survival times, we were pleased to note that our data, although limited, do appear to provide some support of the cutoff point chosen on the basis of the N-stage system of N1 (positive LN < 4, N1a and N1b) and N2 (positive LNZ4). Note that our results should be interpreted with caution because of the small number of patients with N1c; however, we believe that our results provide some additional evidence that TDs might affect survival in a similar manner as positive LN. The association between TD characteristics and prognosis varied in previous studies. Tong et al 16 showed that the number of TDs was not an independent prognostic parameter in the TNM staging system. However, Ueno et al 13 concluded that an increasing number of TDs was significantly relevant to adverse survival outcome in both of their cohorts.
Our study was a single-institution retrospective study, and therefore our results may not be generalizable to the general population. Although we observed certain trends in survival mentioned above, we were not able to fully explore potential group differences and draw firm conclusions due to the small sample sizes in some groups. In particular, further stratification of T3 and T4 within the N1c group was not possible because of the very limited number of T4N1c. Another limitation in our work is that we did not evaluate whether other characteristics of TD, such as location, diameter, and shape, played a role in prognosis because the sample size for N1c was too small. Some of these characteristics might be associated with TD origin, which can be difficult to determine in some cases. Dr Puppa proposed one of the types of TDs to be a conceptual model of in-transit carcinoma, which heralds a high risk for local and systemic recurrence. [21] [22] [23] [24] Additional studies with larger numbers of cases may be helpful to address these issues.
In summary, our study showed that the average number of tumor nodules interpreted as LNs per case and the number of cases with positive LNs were significantly decreased with the seventh edition compared with the fifth/sixth edition; however, the numbers of cases with TDs and <12 LNs were significantly increased with the seventh edition compared with the fifth/sixth edition. These changes, however, resulted in only minimal effects on the final stage grouping. In addition, our results revealed that N1c patients had significantly worse survival compared with N0 patients. Although no statistically significant differences were found between the groups of N1c and N1 or N1c and N2, the HRs indicated that the N1c group might have worse survival than the N1 group and better survival than the N2 group. Therefore, we conclude that TDs predict patient outcome at least similarly to positive LNs. Many questions remain about the definition and origin of TDs. Optimal classification will likely evolve as more outcome studies are completed. 
